Paul T Golumbek, MD, PhD

Assistant Professor of Neurology and of Pediatrics

Phone314-454-6120

Fax314-362-3752

Emailgolumbekp@neuro.wustl.edu

Board Certifications

  • Neurology - Certified
  • Pediatric Neurology - Certified

Related Links

Publications

  • Bibee KP, Cheng YJ, Ching JK, Marsh JN, Li AJ, Keeling RM, Connolly AM, Golumbek PT, Myerson JW, Hu G, Chen J, Shannon WD, Lanza GM, Weihl CC, Wickline SA. Rapamycin nanoparticles target defective autophagy in muscular dystrophy to enhance both strength and cardiac function. FASEB J. 2014 Feb 5. [Epub ahead of print]
  • Connolly AM, Florence JM, Cradock MM, Malkus EC, Schierbecker JR, Siener CA, Wulf CO, Anand P, Golumbek PT, Zaidman CM, Philip Miller J, Lowes LP, Alfano LN, Viollet-Callendret L, Flanigan KM, Mendell JR, McDonald CM, Goude E, Johnson L, Nicorici A, Karachunski PI, Day JW, Dalton JC, Farber JM, Buser KK, Darras BT, Kang PB, Riley SO, Shriber E, Parad R, Bushby K, Eagle M; MDA DMD Clinical Research Network. Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network. Neuromuscul Disord. 2013 Jul;23(7):529-39.
  • Lees JR, Golumbek PT, Sim J, Dorsey D, Russell JH. Regional CNS responses to IFN-gamma determine lesion localization patterns during EAE pathogenesis. J Exp Med. 2008 Oct 27;205(11):2633-42.
  • Golumbek PT, Keeling RM, Connolly AM. RAG2 gene knockout in mice causes fatigue. Muscle Nerve. 2007 Oct;36(4):471-6.
  • Golumbek PT, Keeling RM, Connolly AM. Strength and corticosteroid responsiveness of mdx mice is unchanged by RAG2 gene knockout. Neuromuscul Disord. 2007 May;17(5):376-84. Epub 2007 Apr 23.
  • Keeling RM, Golumbek PT, Streif EM, Connolly AM. Weekly oral prednisolone improves survival and strength in male mdx mice. Muscle Nerve. 2007 Jan;35(1):43-8.
  • Connolly AM, Chez M, Streif EM, Keeling RM, Golumbek PT, Kwon JM, Riviello JJ, Robinson RG, Neuman RJ, Deuel RM. Brain-derived neurotrophic factor and autoantibodies to neural antigens in sera of children with autistic spectrum disorders, Landau-Kleffner syndrome, and epilepsy. Biol Psychiatry. 2006 Feb 15;59(4):354-63. Epub 2005 Sep 21.
  • Golumbek PT, Rho JM, Spain WJ, van Brederode JF. Effects of flunarizine on spontaneous synaptic currents in rat neocortex. Naunyn Schmiedebergs Arch Pharmacol. 2004 Sep;370(3):176-82. Epub 2004 Sep 1.
  • Cross AH, Golumbek PT. Neurologic manifestations of celiac disease: proven, or just a gut feeling? Neurology. 2003 May 27;60(10):1566-8. No abstract available.
  • Golumbek PT, Azhari R, Jaffee EM, Levitsky HI, Lazenby A, Leong K, Pardoll DM. Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res. 1993 Dec 15;53(24):5841-4.
  • Golumbek PT, Hamzeh FM, Jaffee EM, Levitsky H, Lietman PS, Pardoll DM. Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines. J Immunother (1991). 1992 Nov;12(4):224-30.
  • Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M, Pardoll DM. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 1991 Nov 1;254(5032):713-6.
  • Levitsky HI, Golumbek PT, Pardoll DM. The fate of CD4-8- T cell receptor-alpha beta+ thymocytes. J Immunol. 1991 Feb 15;146(4):1113-7.
  • Maity SN, Golumbek PT, Karsenty G, de Crombrugghe B. Selective activation of transcription by a novel CCAAT binding factor. Science. 1988 Jul 29;241(4865):582-5.
  • Hatamochi A, Golumbek PT, Van Schaftingen E, de Crombrugghe B. A CCAAT DNA binding factor consisting of two different components that are both required for DNA binding. J Biol Chem. 1988 Apr 25;263(12):5940-7.

Dr. Golumbek’sspecific interests include disorders of the brain, spinal cord, nerves, and muscles, aswell as general pediatric neurology and neuromuscular diseases.